First proof of pharmacology in humans of a novel glucagon receptor antisense drug

Publisher： John Wiley & Sons Inc

E-ISSN： 1552-4604|55|3|298-306

ISSN： 0091-2700

Source： JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol.55, Iss.3, 2015-03, pp. : 298-306

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist

By  

EPILEPSIA, Vol. 56, Iss. 1, 2015-01 ,pp. : 12-27

John Wiley & Sons Inc

Access to resources Recommend Favorite

The first case of ischemia‐free organ transplantation in humans: A proof of concept

By  

AMERICAN JOURNAL OF TRANSPLANTATION, Vol. 18, Iss. 3, 2018-03 ,pp. : 737-744

John Wiley & Sons Inc

Access to resources Recommend Favorite

Brain reward‐system activation in response to anticipation and consumption of palatable food is altered by glucagon‐like peptide‐1 receptor activation in humans

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 9, 2015-09 ,pp. : 878-886

John Wiley & Sons Inc

Access to resources Recommend Favorite

A first‐in‐human pharmacodynamic and pharmacokinetic study of a fully human anti‐glucagon receptor monoclonal antibody in normal healthy volunteers

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 20, Iss. 2, 2018-02 ,pp. : 283-291

John Wiley & Sons Inc

Access to resources Recommend Favorite

Glucagon receptor as a drug target: A witches' brew of eye of newt (peptides) and toe of frog (receptors)

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 20, Iss. 2, 2018-02 ,pp. : 233-237

John Wiley & Sons Inc

Access to resources Recommend Favorite